These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

403 related articles for article (PubMed ID: 31650290)

  • 1. The prognostic value of serum erythropoietin in patients with lower-risk myelodysplastic syndromes: a review of the literature and expert opinion.
    Park S; Kelaidi C; Meunier M; Casadevall N; Gerds AT; Platzbecker U
    Ann Hematol; 2020 Jan; 99(1):7-19. PubMed ID: 31650290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How we manage adults with myelodysplastic syndrome.
    Fenaux P; Platzbecker U; Ades L
    Br J Haematol; 2020 Jun; 189(6):1016-1027. PubMed ID: 31568568
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Luspatercept in Myelodysplastic Syndromes: Who and When?
    Komrokji RS
    Hematol Oncol Clin North Am; 2020 Apr; 34(2):393-400. PubMed ID: 32089218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lowering the boom on lower-risk myelodysplastic syndromes.
    Sekeres MA; Patel BJ
    Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):367-372. PubMed ID: 31808873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel therapies in low- and high-risk myelodysplastic syndrome.
    Germing U; Schroeder T; Kaivers J; Kündgen A; Kobbe G; Gattermann N
    Expert Rev Hematol; 2019 Oct; 12(10):893-908. PubMed ID: 31353975
    [No Abstract]   [Full Text] [Related]  

  • 6. Prediction of Response to Erythropoiesis Stimulating Agents in Low-Risk Myelodysplastic Syndromes.
    Hattakitpanitchakul S; Kobbuaklee S; Wudhikarn K; Polprasert C
    Asian Pac J Cancer Prev; 2021 Dec; 22(12):4037-4042. PubMed ID: 34967586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Luspatercept as a therapy for myelodysplastic syndromes with ring sideroblasts.
    Schulz F; Nachtkamp K; Kasprzak A; Gattermann N; Haas R; Germing U
    Expert Rev Hematol; 2021 Jun; 14(6):509-516. PubMed ID: 34161752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial.
    Della Porta MG; Garcia-Manero G; Santini V; Zeidan AM; Komrokji RS; Shortt J; Valcárcel D; Jonasova A; Dimicoli-Salazar S; Tiong IS; Lin CC; Li J; Zhang J; Pilot R; Kreitz S; Pozharskaya V; Keeperman KL; Rose S; Prebet T; Lai Y; Degulys A; Paolini S; Cluzeau T; Fenaux P; Platzbecker U
    Lancet Haematol; 2024 Sep; 11(9):e646-e658. PubMed ID: 39038479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome of lower-risk myelodysplastic syndrome with ring sideroblasts (MDS-RS) after failure of erythropoiesis- stimulating agents.
    Park S; Hamel JF; Toma A; Kelaidi C; Thépot S; Campelo MD; Santini V; Sekeres MA; Komrokji R; Steensma D; Balleari E; Götze KS; Kotsianidis I; Guerci-Bresler A; Stamatoullas A; Sanz GF; Germing U; Fenaux P
    Leuk Res; 2020 Dec; 99():106472. PubMed ID: 33212326
    [No Abstract]   [Full Text] [Related]  

  • 10. Luspatercept in low-risk myelodysplastic syndromes: a paradigm shift in treatment strategies.
    Molica M; Rossi M
    Expert Opin Biol Ther; 2024 Apr; 24(4):233-241. PubMed ID: 38555469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study.
    Platzbecker U; Germing U; Götze KS; Kiewe P; Mayer K; Chromik J; Radsak M; Wolff T; Zhang X; Laadem A; Sherman ML; Attie KM; Giagounidis A
    Lancet Oncol; 2017 Oct; 18(10):1338-1347. PubMed ID: 28870615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Luspatercept in combination with recombinant erythropoietin in patients with myelodysplastic syndrome with ring sideroblasts: Stimulating early and late-stage erythropoiesis.
    Fattizzo B; Versino F; Bortolotti M; Rizzo L; Riva M; Barcellini W
    Eur J Haematol; 2023 May; 110(5):571-574. PubMed ID: 36727250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dyserythropoiesis evaluated by the RED score and hepcidin:ferritin ratio predicts response to erythropoietin in lower-risk myelodysplastic syndromes.
    Park S; Kosmider O; Maloisel F; Drenou B; Chapuis N; Lefebvre T; Karim Z; Puy H; Alary AS; Ducamp S; Verdier F; Bouilloux C; Rousseau A; Jacob MC; Debliquis A; Charpentier A; Gyan E; Anglaret B; Leyronnas C; Corm S; Slama B; Cheze S; Laribi K; Amé S; Rose C; Lachenal F; Toma A; Pica GM; Carre M; Garban F; Mariette C; Cahn JY; Meunier M; Herault O; Fenaux P; Wagner-Ballon O; Bardet V; Dreyfus F; Fontenay M
    Haematologica; 2019 Mar; 104(3):497-504. PubMed ID: 30287621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapy for lower-risk MDS.
    Carraway HE; Saygin C
    Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):426-433. PubMed ID: 33275714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes.
    Fenaux P; Platzbecker U; Mufti GJ; Garcia-Manero G; Buckstein R; Santini V; Díez-Campelo M; Finelli C; Cazzola M; Ilhan O; Sekeres MA; Falantes JF; Arrizabalaga B; Salvi F; Giai V; Vyas P; Bowen D; Selleslag D; DeZern AE; Jurcic JG; Germing U; Götze KS; Quesnel B; Beyne-Rauzy O; Cluzeau T; Voso MT; Mazure D; Vellenga E; Greenberg PL; Hellström-Lindberg E; Zeidan AM; Adès L; Verma A; Savona MR; Laadem A; Benzohra A; Zhang J; Rampersad A; Dunshee DR; Linde PG; Sherman ML; Komrokji RS; List AF
    N Engl J Med; 2020 Jan; 382(2):140-151. PubMed ID: 31914241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum erythropoietin (EPO) levels correlate with survival and independently predict response to EPO treatment in patients with myelodysplastic syndromes.
    Wallvik J; Stenke L; Bernell P; Nordahl G; Hippe E; Hast R
    Eur J Haematol; 2002 Mar; 68(3):180-5. PubMed ID: 12068800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Luspatercept in the treatment of lower-risk myelodysplastic syndromes.
    Chan O; Komrokji RS
    Future Oncol; 2021 Apr; 17(12):1473-1481. PubMed ID: 33511859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myelo-deception: Luspatercept & TGF-Beta ligand traps in myeloid diseases & anemia.
    Feld J; Navada SC; Silverman LR
    Leuk Res; 2020 Oct; 97():106430. PubMed ID: 32763582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of luspatercept to treat ineffective erythropoiesis.
    Kubasch AS; Fenaux P; Platzbecker U
    Blood Adv; 2021 Mar; 5(5):1565-1575. PubMed ID: 33687432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Luspatercept: A Review in Transfusion-Dependent Anaemia due to Myelodysplastic Syndromes or β-Thalassaemia.
    Kang C; Syed YY
    Drugs; 2021 Jun; 81(8):945-952. PubMed ID: 33970460
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.